Watch for Elevated BPs From Injectable CGRP Antagonists

April 2021

You may see patients presenting to your ED with elevated BPs from taking an injectable CGRP antagonist used for migraine prophylaxis.

Most data suggest that erenumab (Aimovig) or other CGRP antagonists have minimal CV impact. But it's mostly short-term data in young patients without CV risks.

Now an FDA review suggests new-onset or worsening hypertension with erenumab...prompting labeling updates.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote